Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionAviva Plc
Latest Disclosed Ownership114,003 shares
Latest Disclosed Value $ 37,720,173
Aviva Plc reports 3.02% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 14, 2026 - Aviva Plc filed a 13F-HR form disclosing ownership of 114,003 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $32,570,657 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 110,662 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 3.02% during the quarter. The current value of the position is $28,705,955 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 114,003 3,341 3.02 37,720 -14.28 0.0633
2026-02-12 2025-12-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 110,662 7,456 7.22 44,005 -6.50 0.0742
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 103,206 6,141 6.33 47,062 48.69 0.0855
2025-08-07 2025-06-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 97,065 7,012 7.79 31,652 30.17 0.0654
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 90,053 12,809 16.58 24,316 33.78 0.0587
2025-02-13 2024-12-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 77,244 52,738 215.20 18,176 169.71 0.0472
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 24,506 13,615 125.01 6,740 154.69 0.0175
2024-08-02 2024-06-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 10,891 6,113 127.94 2,647 270.59 0.0073
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 4,778 -3,149 -39.72 714 -52.93 0.0024
2024-02-09 2023-12-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 7,927 -20,481 -72.10 1,517 -69.85 0.0054
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 28,408 20,451 257.02 5,031 232.96 0.0212
2023-08-10 2023-06-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 7,957 -99,215 -92.58 1,511 -92.96 0.0062
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 107,172 -22,668 -17.46 21,469 -30.43 0.0972
2023-02-14 2022-12-31 13F/A-2 ALNYLAM PHARMACEUTICALS IN COM 02043Q107 129,840 42,365 48.43 30,856 76.23 0.1518
2023-02-10 2022-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS IN COM 02043Q107 129,840 42,365 30,856 0.1471
2023-02-09 2022-12-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 129,840 42,365 31 0.1482
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 87,475 4,610 5.56 17,509 44.87 0.1009
2022-08-04 2022-06-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 82,865 9,825 13.45 12,086 1.33 0.0643
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 73,040 34,823 91.12 11,927 84.03 0.0596
2022-02-10 2021-12-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 38,217 1,965 5.42 6,481 -5.32 0.0272
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 36,252 -3,571 -8.97 6,845 1.39 0.0305
2021-08-10 2021-06-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 39,823 1,396 3.63 6,751 24.42 0.0296
2021-05-13 2021-03-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 38,427 -9,613 -20.01 5,426 -13.10 0.0265
2021-02-10 2020-12-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 48,040 -6,125 -11.31 6,244 -20.82 0.0325
2020-11-12 2020-09-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 54,165 799 1.50 7,886 -0.23 0.0465
2020-08-13 2020-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS IN COM 02043Q107 53,366 -5,730 -9.70 7,904 22.87 0.0493
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 53,366 -5,730 7,904 23,928.7980
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 59,096 33,759 133.24 6,433 120.46 0.0471
2020-02-10 2019-12-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 25,337 -1,618 -6.00 2,918 34.59 0.0177
2019-11-12 2019-09-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 26,955 -11,578 -30.05 2,168 -22.46 0.0147
2019-07-30 2019-06-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 38,533 3,882 11.20 2,796 -13.65 0.0192
2019-05-14 2019-03-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 34,651 1,249 3.74 3,238 32.98 0.0217
2019-02-12 2018-12-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 33,402 -9,044 -21.31 2,435 -34.45 0.0182
2018-11-13 2018-09-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 42,446 -1,380 -3.15 3,715 -13.92 0.0204
2018-08-01 2018-06-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 43,826 -29 -0.07 4,316 -17.37 0.0255
2018-05-14 2018-03-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 43,855 43,855 5,223 0.0319
2017-05-15 2017-03-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 0 -48,022 -100.00 0 -100.00
2017-02-13 2016-12-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 48,022 2,793 6.18 1,797 -41.39 0.0107
2016-11-14 2016-09-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 45,229 1,103 2.50 3,066 25.25 0.0191
2016-08-05 2016-06-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 44,126 7,499 20.47 2,448 6.48 0.0168
2016-05-12 2016-03-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 36,627 207 0.57 2,299 -32.95 0.0171
2016-02-11 2015-12-31 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 36,420 -110 -0.30 3,429 16.79 0.0260
2015-11-12 2015-09-30 13F ALNYLAM PHARMACEUTICALS IN COM 02043Q107 36,530 36,530 2,936 0.0243
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.